Abelacimab
Monoclonal antibody
From Wikipedia, the free encyclopedia
Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of thrombosis,[1] under development by Anthos Therapeutics.
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | Factor XI and its active form Factor XIa |
| Clinical data | |
| Other names | MAA868 |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intravenous |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
Mechanism of action
It is anti-factor XI antibody. The hope behind its development is that factor XI plays a bigger role in thrombosis (via the intrinsic/contact activation pathway) than hemostasis, so targeting it might reduce clotting risks without a corresponding increase in bleeding.[1] It has, indeed, shown overwhelming reduction in bleeding as compared to a direct oral anticoagulant (rivaroxaban) in patients with atrial fibrillation and a moderate-to-high risk of stroke.[2] Data is insufficient for drawing a conclusion on whether it increases or decreases stroke events as compared to rivaroxaban.[3]
